Expression and contributions of TRPM7 and KCa2.3/SK3 channels to the increased migration and invasion of microglia in anti-inflammatory activation states

PLoS ONE

Volumn 9, Issue 8, 2014, Pages

  Siddiqui, Tamjeed ^a,b   Lively, Starlee ^a   Ferreira, Roger ^a,b   Wong, Raymond ^a,b   Schlichter, Lyanne C ^a,b  

^a UNIVERSITY HEALTH NETWORK   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

APAMIN; CYTOKINE; DOCEBENONE; ENZYME INHIBITOR; F ACTIN; INTERLEUKIN 10; INTERLEUKIN 4; SMALL CONDUCTANCE CALCIUM ACTIVATED POTASSIUM CHANNEL; TRANSIENT RECEPTOR POTENTIAL CHANNEL M7; (R)-N-(BENZIMIDAZOL-2-YL)-1,2,3,4-TETRAHYDRO-1-NAPHTHYLAMINE; 1 NAPHTHYLAMINE; 2,3,5-TRIMETHYL-6-(12-HYDROXY-5,10-DODECADIYNYL)-1,4-BENZOQUINONE; ANTIINFLAMMATORY AGENT; BENZOQUINONE DERIVATIVE; POTASSIUM CHANNEL BLOCKING AGENT; SK3 PROTEIN, RAT; TRANSIENT RECEPTOR POTENTIAL CHANNEL M; TRPM7 PROTEIN, RAT;

ANIMAL CELL; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CELL INVASION; CELL MIGRATION; ENZYME ACTIVATION; GENE INDUCTION; HUMAN; HUMAN CELL; MICROGLIA; NEWBORN; NONHUMAN; NUCLEOTIDE SEQUENCE; PODOSOME; PROTEIN EXPRESSION; RAT; REGULATORY MECHANISM; ANALOGS AND DERIVATIVES; ANIMAL; ANTAGONISTS AND INHIBITORS; CELL CULTURE; CELL MOTION; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; PATCH CLAMP TECHNIQUE; PATHOLOGY; SPRAGUE DAWLEY RAT;

1-NAPHTHYLAMINE; ANIMALS; ANTI-INFLAMMATORY AGENTS; APAMIN; BENZOQUINONES; CELL MOVEMENT; CELLS, CULTURED; GENE EXPRESSION REGULATION; INTERLEUKIN-10; INTERLEUKIN-4; MICROGLIA; PATCH-CLAMP TECHNIQUES; PODOSOMES; POTASSIUM CHANNEL BLOCKERS; RATS, SPRAGUE-DAWLEY; SMALL-CONDUCTANCE CALCIUM-ACTIVATED POTASSIUM CHANNELS; TRPM CATION CHANNELS;

EID: 84925775377     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0106087     Document Type: Article

References (87)

1. Colton CA (2009) Heterogeneity of microglial activation in the innate immune response in the brain. J Neuroimmune Pharmacol 4: 399-418.
2. Kettenmann H, Hanisch UK, Noda M, Verkhratsky A (2011) Physiology of microglia. Physiol Rev 91: 461-553.
3. Schwartz M, Butovsky O, Bruck W, Hanisch UK (2006) Microglial phenotype: is the commitment reversible? Trends Neurosci 29: 68-74. (Pubitemid 43202595)
4. Hanisch UK, Kettenmann H (2007) Microglia: active sensor and versatile effector cells in the normal and pathologic brain. Nat Neurosci 10: 1387-1394.
5. Harry GJ (2013) Microglia during development and aging. Pharmacol Ther 139: 313-326.
6. Luo XG, Chen SD (2012) The changing phenotype of microglia from homeostasis to disease. Transl Neurodegener 1: 9.
7. Silva SL, Vaz AR, Diogenes MJ, van Rooijen N, Sebastiao AM, et al. (2012) Neuritic growth impairment and cell death by unconjugated bilirubin is mediated by NO and glutamate, modulated by microglia, and prevented by glycoursodeoxycholic acid and interleukin-10. Neuropharmacology 62: 2398-2408.
8. Ledeboer A, Breve JJ, Poole S, Tilders FJ, Van Dam AM (2000) Interleukin-10, interleukin-4, and transforming growth factor-beta differentially regulate lipopolysaccharide-induced production of pro-inflammatory cytokines and nitric oxide in co-cultures of rat astroglial and microglial cells. Glia 30: 134-142. (Pubitemid 30199427)
9. Szczepanik AM, Funes S, Petko W, Ringheim GE (2001) IL-4, IL-10 and IL-13 modulate Aβ(1-42)-induced cytokine and chemokine production in primary murine microglia and a human monocyte cell line. J Neuroimmunol 113: 49-62. (Pubitemid 32008670)
10. Michelucci A, Heurtaux T, Grandbarbe L, Morga E, Heuschling P (2009) Characterization of the microglial phenotype under specific pro-inflammatory and anti-inflammatory conditions: Effects of oligomeric and fibrillar amyloid-β. J Neuroimmunol 210: 3-12.
11. Smith ME, van der Maesen K, Somera FP (1998) Macrophage and microglial responses to cytokines in vitro: phagocytic activity, proteolytic enzyme release, and free radical production. J Neurosci Res 54: 68-78. (Pubitemid 28447190)
12. Chhor V, Le Charpentier T, Lebon S, Ore MV, Celador IL, et al. (2013) Characterization of phenotype markers and neuronotoxic potential of polarised primary microglia in vitro. Brain Behav Immun 32: 70-85.
13. Lively S, Schlichter LC (2013) The microglial activation state regulates migration and roles of matrix-dissolving enzymes for invasion. J Neuroinflammation 10: 75.
14. Linder S, Wiesner C, Himmel M (2011) Degrading devices: invadosomes in proteolytic cell invasion. Annu Rev Cell Dev Biol 27: 185-211.
15. Murphy DA, Courtneidge SA (2011) The 'ins' and 'outs' of podosomes and invadopodia: characteristics, formation and function. Nat Rev Mol Cell Biol 12: 413-426.
16. Vincent C, Siddiqui TA, Schlichter LC (2012) Podosomes in migrating microglia: components and matrix degradation. J Neuroinflammation 9: 190.
17. Siddiqui TA, Lively S, Vincent C, Schlichter LC (2012) Regulation of podosome formation, microglial migration and invasion by Ca2+- signaling molecules expressed in podosomes. J Neuroinflammation 9: 250.
18. Chubanov V, Mederos y Schnitzler M, Meissner M, Schafer S, Abstiens K, et al. (2012) Natural and synthetic modulators of SK (KCa2) potassium channels inhibit magnesium-dependent activity of the kinase-coupled cation channel TRPM7. Br J Pharmacol 166: 1357-1376.
19. Jiang X, Newell EW, Schlichter LC (2003) Regulation of a TRPM7-like current in rat brain microglia. J Biol Chem 278: 42867-42876. (Pubitemid 37345896)
20. Ohana L, Newell EW, Stanley EF, Schlichter LC (2009) The Ca2+ release-activated Ca2+ current (ICRAC) mediates store-operated Ca2+ entry in rat microglia. Channels (Austin) 3: 129-139.
21. Liu BS, Ferreira R, Lively S, Schlichter LC (2013) Microglial SK3 and SK4 currents and activation state are modulated by the neuroprotective drug, riluzole. J Neuroimmune Pharmacol 8: 227-237.
22. Ferreira R, Lively S, Schlichter LC (2014) IL-4 type1 receptor signaling upregulates KCNN4 expression, and increases the KCa3.1 current and its contribution to migration of alternative-activated microglia. Front. Cell. Neurosci. Vol 8, Article 183; doi:10.3389/fncel.2014.00183.
23. Sivagnanam V, Zhu X, Schlichter LC (2010) Dominance of E. coli phagocytosis over LPS in the inflammatory response of microglia. J Neuroimmunol 227: 111-119.
24. Zhou W, Cayabyab FS, Pennefather PS, Schlichter LC, DeCoursey TE (1998) HERG-like K+ channels in microglia. J Gen Physiol 111: 781-794.
25. Schlichter LC, Mertens T, Liu B (2011) Swelling activated Cl- channels in microglia: Biophysics, pharmacology and role in glutamate release. Channels (Austin) 5: 128-137.
26. Ferreira R, Schlichter LC (2013) Selective activation of KCa3.1 and CRAC channels by P2Y2 receptors promotes Ca2+ signaling, store refilling and migration of rat microglial cells. PLoS One 8: e62345.
27. Cayabyab FS, Khanna R, Jones OT, Schlichter LC (2000) Suppression of the rat microglia Kv1.3 current by src-family tyrosine kinases and oxygen/glucose deprivation. Eur J Neurosci 12: 1949-1960. (Pubitemid 30348834)
28. Cayabyab FS, Schlichter LC (2002) Regulation of an ERG K+ current by Src tyrosine kinase. J Biol Chem 277: 13673-13681.
29. Cayabyab FS, Tsui FW, Schlichter LC (2002) Modulation of the ERG K + current by the tyrosine phosphatase, SHP-1. J Biol Chem 277: 48130-48138.
30. Newell EW, Schlichter LC (2005) Integration of K+ and Cl - currents regulate steady-state and dynamic membrane potentials in cultured rat microglia. J Physiol 567: 869-890.
31. Schlichter LC, Sakellaropoulos G, Ballyk B, Pennefather PS, Phipps DJ (1996) Properties of K+ and Cl- channels and their involvement in proliferation of rat microglial cells. Glia 17: 225-236.
32. Girard S, Brough D, Lopez-Castejon G, Giles J, Rothwell NJ, et al. (2013) Microglia and macrophages differentially modulate cell death after brain injury caused by oxygen-glucose deprivation in organotypic brain slices. Glia 61: 813-824.
33. Yang MS, Ji KA, Jeon SB, Jin BK, Kim SU, et al. (2006) Interleukin-13 enhances cyclooxygenase-2 expression in activated rat brain microglia: implications for death of activated microglia. J Immunol 177: 1323-1329. (Pubitemid 44036639)
34. Kremlev SG, Palmer C (2005) Interleukin-10 inhibits endotoxin-induced proinflammatory cytokines in microglial cell cultures. J Neuroimmunol 162: 71-80.
35. Lim SH, Park E, You B, Jung Y, Park AR, et al. (2013) Neuronal synapse formation induced by microglia and interleukin 10. PLoS One 8: e81218.
36. Grunnet M, Jespersen T, Angelo K, Frokjaer-Jensen C, Klaerke DA, et al. (2001) Pharmacological modulation of SK3 channels. Neuropharmacology 40: 879-887. (Pubitemid 32510801)
37. Pedarzani P, D'Hoedt D, Doorty KB, Wadsworth JD, Joseph JS, et al. (2002) Tamapin, a venom peptide from the Indian red scorpion (Mesobuthus tamulus) that targets small conductance Ca2+-activated K+ channels and afterhyperpolarization currents in central neurons. J Biol Chem 277: 46101-46109.
38. Strobaek D, Hougaard C, Johansen TH, Sorensen US, Nielsen EO, et al. (2006) Inhibitory gating modulation of small conductance Ca2+- activated K+ channels by the synthetic compound (R)-N-(benzimidazol- 2-yl)-1,2,3,4-tetrahydro-1-naphtylamine (NS8593) reduces afterhyperpolarizing current in hippocampal CA1 neurons. Mol Pharmacol 70: 1771-1782.
39. Chen HC, Xie J, Zhang Z, Su LT, Yue L, et al. (2010) Blockade of TRPM7 channel activity and cell death by inhibitors of 5-lipoxygenase. PLoS One 5: e11161.
40. Monteilh-Zoller MK, Hermosura MC, Nadler MJ, Scharenberg AM, Penner R, et al. (2003) TRPM7 provides an ion channel mechanism for cellular entry of trace metal ions. J Gen Physiol 121: 49-60. (Pubitemid 36133936)
41. Nadler MJ, Hermosura MC, Inabe K, Perraud AL, Zhu Q, et al. (2001) LTRPC7 is a Mg.ATP-regulated divalent cation channel required for cell viability. Nature 411: 590-595. (Pubitemid 32531406)
42. Pello OM, De Pizzol M, Mirolo M, Soucek L, Zammataro L, et al. (2012) Role of c-MYC in alternative activation of human macrophages and tumor-associated macrophage biology. Blood 119: 411-421.
43. Foresti R, Bains SK, Pitchumony TS, de Castro Bras LE, Drago F, et al. (2013) Small molecule activators of the Nrf2-HO-1 antioxidant axis modulate heme metabolism and inflammation in BV2 microglia cells. Pharmacol Res 76: 132-148.
44. Perrier S, Darakhshan F, Hajduch E (2006) IL-1 receptor antagonist in metabolic diseases: Dr Jekyll or Mr Hyde? FEBS Lett 580: 6289-6294. (Pubitemid 44750933)
45. Sica A, Mantovani A (2012) Macrophage plasticity and polarization: in vivo veritas. J Clin Invest 122: 787-795.
46. Rojo AI, Innamorato NG, Martin-Moreno AM, De Ceballos ML, Yamamoto M, et al. (2010) Nrf2 regulates microglial dynamics and neuroinflammation in experimental Parkinson's disease. Glia 58: 588-598.
47. Kohler M, Hirschberg B, Bond CT, Kinzie JM, Marrion NV, et al. (1996) Small-conductance, calcium-activated potassium channels from mammalian brain. Science 273: 1709-1714. (Pubitemid 26317786)
48. Mederos y Schnitzler M, Waring J, Gudermann T, Chubanov V (2008) Evolutionary determinants of divergent calcium selectivity of TRPM channels. Faseb J 22: 1540-1551. (Pubitemid 351656794)
49. Park HS, Hong C, Kim BJ, So I (2014) The pathophysiologic roles of TRPM7 channel. Korean J Physiol Pharmacol 18: 15-23.
50. Romani AM, Scarpa A (2000) Regulation of cellular magnesium. Front Biosci 5: D720-734.
51. Qian L, Block ML, Wei SJ, Lin CF, Reece J, et al. (2006) Interleukin-10 protects lipopolysaccharide-induced neurotoxicity in primary midbrain cultures by inhibiting the function of NADPH oxidase. J Pharmacol Exp Ther 319: 44-52. (Pubitemid 44455109)
52. Won SY, Kim SR, Maeng S, Jin BK (2013) Interleukin-13/Interleukin-4- induced oxidative stress contributes to death of prothrombinkringle-2 (pKr-2)-activated microglia. J Neuroimmunol 265: 36-42.
53. Zhao W, Xie W, Xiao Q, Beers DR, Appel SH (2006) Protective effects of an anti-inflammatory cytokine, interleukin-4, on motoneuron toxicity induced by activated microglia. J Neurochem 99: 1176-1187. (Pubitemid 44655283)
54. Fouda AY, Kozak A, Alhusban A, Switzer JA, Fagan SC (2013) Anti-inflammatory IL-10 is upregulated in both hemispheres after experimental ischemic stroke: Hypertension blunts the response. Exp Transl Stroke Med 5: 12.
55. Wasserman JK, Zhu X, Schlichter LC (2007) Evolution of the inflammatory response in the brain following intracerebral hemorrhage and effects of delayed minocycline treatment. Brain Res 1180: 140-154. (Pubitemid 350018735)
56. Hu X, Li P, Guo Y, Wang H, Leak RK, et al. (2012) Microglia/macrophage polarization dynamics reveal novel mechanism of injury expansion after focal cerebral ischemia. Stroke 43: 3063-3070.
57. Ouyang W, Rutz S, Crellin NK, Valdez PA, Hymowitz SG (2011) Regulation and functions of the IL-10 family of cytokines in inflammation and disease. Annu Rev Immunol 29: 71-109.
58. Moxon-Emre I, Schlichter LC (2011) Neutrophil depletion reduces blood-brain barrier breakdown, axon injury, and inflammation after intracerebral hemorrhage. J Neuropathol Exp Neurol 70: 218-235.
59. Wasserman JK, Schlichter LC (2008) White matter injury in young and aged rats after intracerebral hemorrhage. Exp Neurol 214: 266-275.
60. Moxon-Emre I, Schlichter LC (2010) Evolution of inflammation and white matter injury in a model of transient focal ischemia. J Neuropathol Exp Neurol 69: 1-15.
61. Kaushal V, Koeberle PD, Wang Y, Schlichter LC (2007) The Ca 2+-activated K+ channel KCNN4/KCa3.1 contributes to microglia activation and nitric oxide-dependent neurodegeneration. J Neurosci 27: 234-244.
62. Koeberle PD, Schlichter LC (2010) Targeting KV channels rescues retinal ganglion cells in vivo directly and by reducing inflammation. Channels (Austin) 4: 337-346.
63. Bouhy D, Ghasemlou N, Lively S, Redensek A, Rathore KI, et al. (2011) Inhibition of the Ca2+-dependent K+ channel, KCNN4/KCa3.1, improves tissue protection and locomotor recovery after spinal cord injury. J Neurosci 31: 16298-16308.
64. Mashimo H, Ohguro N, Nomura S, Hashida N, Nakai K, et al. (2008) Neutrophil chemotaxis and local expression of interleukin-10 in the tolerance of endotoxin-induced uveitis. Invest Ophthalmol Vis Sci 49: 5450-5457.
65. Lindenberg JJ, Oosterhoff D, Sombroek CC, Lougheed SM, Hooijberg E, et al. (2013) IL-10 conditioning of human skin affects the distribution of migratory dendritic cell subsets and functional T cell differentiation. PLoS One 8: e70237.
66. Liebau S, Vaida B, Proepper C, Grissmer S, Storch A, et al. (2007) Formation of cellular projections in neural progenitor cells depends on SK3 channel activity. J Neurochem 101: 1338-1350. (Pubitemid 46718816)
67. Chantome A, Girault A, Potier M, Collin C, Vaudin P, et al. (2009) KCa2.3 channel-dependent hyperpolarization increases melanoma cell motility. Exp Cell Res 315: 3620-3630.
68. Jelassi B, Chantome A, Alcaraz-Perez F, Baroja-Mazo A, Cayuela ML, et al. (2011) P2X7 receptor activation enhances SK3 channels- and cystein cathepsin-dependent cancer cells invasiveness. Oncogene 30: 2108-2122.
69. Potier M, Joulin V, Roger S, Besson P, Jourdan ML, et al. (2006) Identification of SK3 channel as a new mediator of breast cancer cell migration. Mol Cancer Ther 5: 2946-2953. (Pubitemid 44849022)
70. Potier M, Chantome A, Joulin V, Girault A, Roger S, et al. (2011) The SK3/KCa2.3 potassium channel is a new cellular target for edelfosine. Br J Pharmacol 162: 464-479.
71. Chantome A, Potier-Cartereau M, Clarysse L, Fromont G, Marionneau-Lambot S, et al. (2013) Pivotal role of the lipid Raft SK3-Orai1 complex in human cancer cell migration and bone metastases. Cancer Res 73: 4852-4861.
72. Asrar S, Aarts M (2013) TRPM7, the cytoskeleton and neuronal death. Channels (Austin) 7: 6-16.
73. Bates-Withers C, Sah R, Clapham DE (2011) TRPM7, the Mg2+ inhibited channel and kinase. Adv Exp Med Biol 704: 173-183.
74. Aarts MM, Tymianski M (2005) TRPM7 and ischemic CNS injury. Neuroscientist 11: 116-123. (Pubitemid 40388494)
75. Pla FA, Gkika D (2013) Emerging role of TRP channels in cell migration: from tumor vascularization to metastasis. Front Physiol 4: 311.
76. Wei C, Wang X, Chen M, Ouyang K, Song LS, et al. (2009) Calcium flickers steer cell migration. Nature 457: 901-905.
77. Visser D, Langeslag M, Kedziora KM, Klarenbeek J, Kamermans A, et al. (2013) TRPM7 triggers Ca2+ sparks and invadosome formation in neuroblastoma cells. Cell Calcium 54: 404-415.
78. Clark K, Langeslag M, van Leeuwen B, Ran L, Ryazanov AG, et al. (2006) TRPM7, a novel regulator of actomyosin contractility and cell adhesion. Embo J 25: 290-301. (Pubitemid 43152850)
79. Clark K, Middelbeek J, Lasonder E, Dulyaninova NG, Morrice NA, et al. (2008) TRPM7 regulates myosin IIA filament stability and protein localization by heavy chain phosphorylation. J Mol Biol 378: 790-803.
80. Su LT, Agapito MA, Li M, Simonson WT, Huttenlocher A, et al. (2006) TRPM7 regulates cell adhesion by controlling the calcium-dependent protease calpain. J Biol Chem 281: 11260-11270. (Pubitemid 43855551)
81. Kuras Z, Yun YH, Chimote AA, Neumeier L, Conforti L (2012) KCa3.1 and TRPM7 channels at the uropod regulate migration of activated human T cells. PLoS One 7: e43859.
82. Bae CY, Sun HS (2013) Current understanding of TRPM7 pharmacology and drug development for stroke. Acta Pharmacol Sin 34: 10-16.
83. Demeuse P, Penner R, Fleig A (2006) TRPM7 channel is regulated by magnesium nucleotides via its kinase domain. J Gen Physiol 127: 421-434.
84. Takezawa R, Schmitz C, Demeuse P, Scharenberg AM, Penner R, et al. (2004) Receptor-mediated regulation of the TRPM7 channel through its endogenous protein kinase domain. Proc Natl Acad Sci U S A 101: 6009-6014. (Pubitemid 38520519)
85. Runnels LW, Yue L, Clapham DE (2002) The TRPM7 channel is inactivated by PIP2 hydrolysis. Nat Cell Biol 4: 329-336.
86. Penner R, Fleig A (2007) The Mg2+ and Mg2+- nucleotide-regulated channelkinase TRPM7. Handb Exp Pharmacol: 313-328.
87. Jiang H, Harris MB, Rothman P (2000) IL-4/IL-13 signaling beyond JAK/STAT. J Allergy Clin Immunol 105: 1063-1070. (Pubitemid 30418781)